Resiliency outcomes after participation in an asynchronous web-based platform for adults with neurofibromatosis: The NF-Web study

Author:

Wang Katherine E.ORCID,Vranceanu Ana-Maria,Lester Ethan G.ORCID

Abstract

The purpose of this study was to analyze secondary resiliency and user experience outcomes from a novel, 8-week website-based mind-body intervention (NF-Web) for adults (18+) with neurofibromatosis (NF1, NF2, and schwannomatosis), a genetic, neurocutaneous disorder characterized by nerve sheath tumors of the central and peripheral nervous system. The study design was a secondary data analysis of a single-arm, early feasibility pilot study (September 2020-May 2021) for adults with NF (N = 28). Across participants, the mean age was 46 (SD = 13.67) and included 22 females and 6 males. Participants completed baseline and posttest assessments (t-tests), as well as exit interviews (exploratory rapid data analysis). Results demonstrated that participation was associated with pre-to-post improvements in gratitude, coping, and mindfulness (p < .05). Exit interviews indicated participant enjoyment and that many would recommend NF-Web to a friend. Participants found the website easy to navigate and enjoyed NF-Web’s video format. Many found transcripts useful if they had hearing differences or if English was their second language. NF-Web demonstrated initial signals of improvement in resiliency outcomes and positive user experience. Future pilot RCTs will explore these changes by NF type.

Funder

Children's Tumor Foundation

NF Northeast

NF Midwest

TNFF

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference44 articles.

1. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis;R. Tamura;Int J Mol Sci,2021

2. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service;DG Evans;Am J Med Genet A,2010

3. The neurofibromatoses. Part 2: NF2 and schwannomatosis;C Lu-Emerson;Rev Neurol Dis,2009

4. The Neurofibromatoses;S Farschtschi;Dtsch Arztebl Int,2020

5. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus;PMK de Blank;Neuro-Oncology,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3